Improving drug effectiveness by controlling molecular structure
Official title: Stereochemical Editing of Quaternary Stereocenters Enabled by Enantioselective Recombination of C–C Bonds
Funded at Massachusetts Institute of Technology · NIH-11044034 · Data updated 2026-11-12
This study is exploring a new way to make medicines work better and have fewer side effects by carefully changing their molecular structure, which could help improve treatments for patients.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project start | January 19, 2024 |
| Project end | January 18, 2027 |
| Funding year | 2025 |
| Award (this year) | $73,828 |
| NIH project number | 5F32GM153117-02 |
| Project ID | NIH-11044034 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for benefiting from this research include patients who require medications with specific stereochemical properties for optimal therapeutic effects.
✕Less likely to help
Patients who are not taking medications that rely on stereochemical properties may not benefit from this research.
What this research studies
This research focuses on enhancing the effectiveness of pharmaceutical drugs by precisely controlling their molecular structure, specifically targeting quaternary stereocenters. It aims to develop a new method for stereochemical editing that allows for the selective modification of these complex molecules using advanced techniques in synthetic organic chemistry. By employing a dual catalytic system that combines photoredox and nickel catalysis, the researchers hope to create a more efficient way to achieve the desired stereochemistry in drug compounds. This could lead to improved drug efficacy and reduced side effects for patients.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective and safer drugs tailored to individual patient needs.
How similar studies have gone: Other research has shown promise in using catalytic methods for stereochemical editing, indicating that this approach could be a significant advancement in drug development.
Where this research is happening
-
Massachusetts Institute of Technology
Cambridge, United States Active
Researchers
- Principal investigator: Hwang, Taehwan — Massachusetts Institute of Technology
- Study coordinator: Hwang, Taehwan
Related research
Other NIH-funded projects on the same topics.
-
PhysioNet: A trusted, open data repository for clinical and physiological data
A publicly accessible platform provides curated clinical and physiological data and tools to help researchers develop and test AI models for better healthcare.
-
Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate
Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.
-
Single-cell, label-free mapping of senescence in tissues with Raman imaging and spatial genomics
A project to map how senescent cells differ across tissues using a noninvasive Raman imaging method combined with spatial genomics.
-
Structures and dynamics of virus ion channels
This project studies the tiny channels in certain influenza and coronavirus viruses to understand how they let ions pass through and contribute to disease.
-
Prospect: Stem Cell Models for Early-Onset Colorectal Cancer Prevention
Researchers at MIT are using stem cell models to understand why colorectal cancer is rising in people under 50 and how to prevent it.
-
MATCHMAKERS: AI tools to predict TCR binding and design
Researchers are building AI tools to predict how T cell receptors recognize tumor antigens, with aims to help improve targeted immunotherapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.